PASG
Passage Bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.65
−2.11%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 129.0K | 728.0K | — | 3.7M | — |
| Gross Profit | (129.0K) | (728.0K) | — | (3.7M) | — |
| Operating Expenses | |||||
| R&D Expense | 17.2M | 23.3M | 40.2M | 59.6M | 86.1M |
| SG&A Expense | 20.9M | 19.9M | 25.0M | 41.6M | 49.3M |
| General & Admin Expense | 20.9M | 19.9M | 25.0M | 41.6M | 49.3M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 1.4M | (728.0K) | 5.2M | (4.7M) | 3.0M |
| Total Operating Expenses | 39.5M | 42.4M | 70.4M | 96.4M | 138.4M |
| Cost and Expenses | 39.7M | 43.2M | 70.4M | 100.1M | 138.4M |
| Operating Income (EBIT) | (39.7M) | (43.2M) | (70.4M) | (100.1M) | (138.4M) |
| Non-Operating | |||||
| Interest Income | — | 2.3M | 4.3M | 5.6M | 2.3M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | 2.3M | 4.3M | 5.6M | 2.3M |
| Other Non-Op Income/Expense | 3.5M | (2.4M) | 5.6M | (1.9M) | 2.3M |
| Non-Operating Income (excl Interest) | (6.2M) | 2.4M | (5.2M) | 1.9M | (3.0M) |
| EBT (Pre-Tax Income) | (36.1M) | (45.5M) | (64.8M) | (102.1M) | (136.1M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (36.1M) | (45.5M) | (64.8M) | (102.1M) | (136.1M) |
| Earnings from Cont. Ops | (36.1M) | (45.5M) | (64.8M) | (102.1M) | (136.1M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (36.1M) | (45.5M) | (64.8M) | (102.1M) | (136.1M) |
| Per Share | |||||
| Basic EPS | ($11.33) | ($14.35) | ($21.44) | ($37.29) | ($50.00) |
| Diluted EPS | ($11.33) | ($14.35) | ($21.44) | ($37.29) | ($50.00) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 3.2M | 3.2M | 3.0M | 2.7M | 2.7M |
| Diluted Shares Outstanding | 3.2M | 3.2M | 3.0M | 2.7M | 2.7M |
| Profitability Metrics | |||||
| EBITDA | (32.8M) | (44.8M) | (62.1M) | (98.3M) | (131.7M) |
| D&A | 642.0K | 728.0K | 3.1M | 3.7M | 3.7M |
| EBIT | (33.5M) | (45.5M) | (65.2M) | (102.1M) | (135.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026